BirchBioMed is a clinical-stage biomedical company
focused on the clinical evaluation, development and commercialization of anti-scarring drugs,
autoimmune therapeutics and novel strategies for transplantation.

BIRCHBIOMED IS CLEARED TO BEGIN
FIRST-OF-ITS-KIND PHASE II CLINICAL TRIAL